Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
The grant is designated for the research and development of Pyronaridine
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
e brings over 27+ years of rich pharmaceutical experience
Subscribe To Our Newsletter & Stay Updated
